Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (5): 430-434.DOI: 10.3969/j.issn.1673-8640.2023.05.005
Previous Articles Next Articles
YU Qi, WANG Yanchun, GUO Lin, LU Renquan()
Received:
2022-09-29
Revised:
2023-02-27
Online:
2023-05-30
Published:
2023-08-07
CLC Number:
YU Qi, WANG Yanchun, GUO Lin, LU Renquan. Influence of particle radiotherapy on bone marrow,liver and kidney functions in patients with prostate cancer[J]. Laboratory Medicine, 2023, 38(5): 430-434.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.05.005
组别 | 例数 | 风险等级 | TNM分期 | 治疗前PSA水平 | 同步内分泌 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
中/ [例(%)] | 高/ [例(%)] | Ⅰ~Ⅱ期/[例(%)] | Ⅲ~Ⅳ期/[例(%)] | ≤10 ng/mL/[例(%)] | >10 ng/mL/[例(%)] | 是/ [例(%)] | 否/ [例(%)] | |||||
光子放疗组 | 23 | 6(26) | 17(74) | 6(74) | 17(74) | 21(91) | 2(9) | 15(65) | 8(35) | |||
重离子放疗组 | 25 | 10(40) | 15(60) | 11(44) | 14(56) | 22(88) | 3(12) | 13(52) | 12(48) | |||
质子重离子放疗组 | 28 | 4(14) | 24(86) | 8(29) | 20(71) | 27(96) | 1(4) | 20(71) | 8(29) | |||
χ2值 | 0.237 | 0.269 | 0.131 | 0.168 | ||||||||
P值 | 0.105 | 0.052 | 0.517 | 0.332 |
组别 | 例数 | 风险等级 | TNM分期 | 治疗前PSA水平 | 同步内分泌 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
中/ [例(%)] | 高/ [例(%)] | Ⅰ~Ⅱ期/[例(%)] | Ⅲ~Ⅳ期/[例(%)] | ≤10 ng/mL/[例(%)] | >10 ng/mL/[例(%)] | 是/ [例(%)] | 否/ [例(%)] | |||||
光子放疗组 | 23 | 6(26) | 17(74) | 6(74) | 17(74) | 21(91) | 2(9) | 15(65) | 8(35) | |||
重离子放疗组 | 25 | 10(40) | 15(60) | 11(44) | 14(56) | 22(88) | 3(12) | 13(52) | 12(48) | |||
质子重离子放疗组 | 28 | 4(14) | 24(86) | 8(29) | 20(71) | 27(96) | 1(4) | 20(71) | 8(29) | |||
χ2值 | 0.237 | 0.269 | 0.131 | 0.168 | ||||||||
P值 | 0.105 | 0.052 | 0.517 | 0.332 |
组别 | 例数 | WBC计数/(×109/L) | LYMPH#/ (×109/L) | Hb/(g/L) | PLT计数/ (×109/L) | Alb/(g/L) | ||
---|---|---|---|---|---|---|---|---|
光子放疗组 | 23 | 5.7 (5.2~7.2) | 2.2 (1.3~2.3) | 129.0 (104.0~137.0) | 181.0(154.0~205.0) | 42.5(38.8~45.1) | ||
重离子放疗组 | 25 | 6.0 (4.9~6.8) | 1.7 (1.3~2.3) | 139.0 (128.0~144.5) | 178.0(162.5~231.0) | 46.5(44.8~49.0) | ||
质子重离子放疗组 | 28 | 5.5 (4.8~7.0) | 1.45 (1.1~1.9) | 134.0 (127.0~143.0) | 195.5(171.3~220.8) | 45.0(43.4~47.8) | ||
H值 | 0.741 | 6.492 | 5.938 | 1.24 | 20.166 | |||
P值 | 0.690 | 0.039 | 0.051 | 0.538 | <0.001 | |||
组别 | TB/(μmol/L) | ALT/(U/L) | AST/(U/L) | Cr/(μmol/L) | 尿素/(mmol/L) | |||
光子放疗组 | 9.6(7.0~14.1) | 16.6(11.0~22.7) | 17.3(16.1~21.4) | 78.0(66.0~83.0) | 6.4(5.4~7.0) | |||
重离子放疗组 | 9.8(8.7~11.9) | 20.5(17.1~32.7) | 21.3(17.6~26.2) | 68.0(60.3~78.0) | 5.9(4.7~7.2) | |||
质子重离子放疗组 | 12.1(9.3~14.5) | 20.9(15.9~29.9) | 21.2(17.6~27.3) | 83.0(71.0~89.5) | 5.9(4.7~6.6) | |||
H值 | 1.717 | 5.847 | 7.992 | 9.815 | 1.967 | |||
P值 | 0.424 | 0.054 | 0.018 | 0.007 | 0.374 |
组别 | 例数 | WBC计数/(×109/L) | LYMPH#/ (×109/L) | Hb/(g/L) | PLT计数/ (×109/L) | Alb/(g/L) | ||
---|---|---|---|---|---|---|---|---|
光子放疗组 | 23 | 5.7 (5.2~7.2) | 2.2 (1.3~2.3) | 129.0 (104.0~137.0) | 181.0(154.0~205.0) | 42.5(38.8~45.1) | ||
重离子放疗组 | 25 | 6.0 (4.9~6.8) | 1.7 (1.3~2.3) | 139.0 (128.0~144.5) | 178.0(162.5~231.0) | 46.5(44.8~49.0) | ||
质子重离子放疗组 | 28 | 5.5 (4.8~7.0) | 1.45 (1.1~1.9) | 134.0 (127.0~143.0) | 195.5(171.3~220.8) | 45.0(43.4~47.8) | ||
H值 | 0.741 | 6.492 | 5.938 | 1.24 | 20.166 | |||
P值 | 0.690 | 0.039 | 0.051 | 0.538 | <0.001 | |||
组别 | TB/(μmol/L) | ALT/(U/L) | AST/(U/L) | Cr/(μmol/L) | 尿素/(mmol/L) | |||
光子放疗组 | 9.6(7.0~14.1) | 16.6(11.0~22.7) | 17.3(16.1~21.4) | 78.0(66.0~83.0) | 6.4(5.4~7.0) | |||
重离子放疗组 | 9.8(8.7~11.9) | 20.5(17.1~32.7) | 21.3(17.6~26.2) | 68.0(60.3~78.0) | 5.9(4.7~7.2) | |||
质子重离子放疗组 | 12.1(9.3~14.5) | 20.9(15.9~29.9) | 21.2(17.6~27.3) | 83.0(71.0~89.5) | 5.9(4.7~6.6) | |||
H值 | 1.717 | 5.847 | 7.992 | 9.815 | 1.967 | |||
P值 | 0.424 | 0.054 | 0.018 | 0.007 | 0.374 |
组别 | 例数 | LYMPH# | Hb | |||||
---|---|---|---|---|---|---|---|---|
Ⅰ级 | Ⅱ级 | Ⅲ~Ⅳ级 | Ⅰ级 | Ⅱ级 | Ⅲ~Ⅳ级 | |||
光子放疗组 | 23 | 9(39) | 12(52) | 2(9) | 18(79) | 4(17) | 1(4) | |
重离子放疗组 | 25 | 25(100) | 0(0) | 0(0) | 25(100) | 0(0) | 0(0) | |
质子重离子放疗组 | 28 | 11(39) | 15(54) | 2(7) | 28(100) | 0(0) | 0(0) | |
χ2值 | 25.729 | 12.333 | ||||||
P值 | <0.001 | 0.015 |
组别 | 例数 | LYMPH# | Hb | |||||
---|---|---|---|---|---|---|---|---|
Ⅰ级 | Ⅱ级 | Ⅲ~Ⅳ级 | Ⅰ级 | Ⅱ级 | Ⅲ~Ⅳ级 | |||
光子放疗组 | 23 | 9(39) | 12(52) | 2(9) | 18(79) | 4(17) | 1(4) | |
重离子放疗组 | 25 | 25(100) | 0(0) | 0(0) | 25(100) | 0(0) | 0(0) | |
质子重离子放疗组 | 28 | 11(39) | 15(54) | 2(7) | 28(100) | 0(0) | 0(0) | |
χ2值 | 25.729 | 12.333 | ||||||
P值 | <0.001 | 0.015 |
组别 | 单纯放疗 | 放疗同步内分泌治疗 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | LYMPH# | 例数 | LYMPH# | Hb | |||||||||
Ⅰ级/ [例(%)] | Ⅱ级/ [例(%)] | Ⅲ~Ⅳ级/[例(%)] | Ⅰ级/[例(%)] | Ⅱ级/[例(%)] | Ⅲ~Ⅳ级/[例(%)] | Ⅰ级/[例(%)] | Ⅱ级/[例(%)] | Ⅲ~Ⅳ级/[例(%)] | |||||
光子放疗组 | 8 | 4(50) | 4(50) | 0(0) | 15 | 5(33) | 8(54) | 2(13) | 11(73) | 3(20) | 1(7) | ||
重离子放疗组 | 12 | 12(100) | 0(0) | 0(0) | 13 | 13(100) | 0(0) | 0(0) | 13(100) | 0(0) | 0(0) | ||
质子重离子组放疗组 | 8 | 4(50) | 4(50) | 0(0) | 20 | 7(26) | 11(55) | 2(10) | 20(100) | 0(0) | 0(0) | ||
χ2值 | 8.400 | 16.527 | 9.600 | ||||||||||
P值 | 0.015 | 0.002 | 0.048 |
组别 | 单纯放疗 | 放疗同步内分泌治疗 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
例数 | LYMPH# | 例数 | LYMPH# | Hb | |||||||||
Ⅰ级/ [例(%)] | Ⅱ级/ [例(%)] | Ⅲ~Ⅳ级/[例(%)] | Ⅰ级/[例(%)] | Ⅱ级/[例(%)] | Ⅲ~Ⅳ级/[例(%)] | Ⅰ级/[例(%)] | Ⅱ级/[例(%)] | Ⅲ~Ⅳ级/[例(%)] | |||||
光子放疗组 | 8 | 4(50) | 4(50) | 0(0) | 15 | 5(33) | 8(54) | 2(13) | 11(73) | 3(20) | 1(7) | ||
重离子放疗组 | 12 | 12(100) | 0(0) | 0(0) | 13 | 13(100) | 0(0) | 0(0) | 13(100) | 0(0) | 0(0) | ||
质子重离子组放疗组 | 8 | 4(50) | 4(50) | 0(0) | 20 | 7(26) | 11(55) | 2(10) | 20(100) | 0(0) | 0(0) | ||
χ2值 | 8.400 | 16.527 | 9.600 | ||||||||||
P值 | 0.015 | 0.002 | 0.048 |
治疗方案 | 例数 | ALT/(U/L) | Cr/(μmol/L) | Alb(g/L) | TB/(μmol/L) | AST/(U/L) | Cr/(μmol/L) |
---|---|---|---|---|---|---|---|
光子放疗同步 内分泌治疗 | 15 | ||||||
放疗前 | 12.6 (10.8~19.9) | 75.0 (64.0~84.0) | 42.7 (38.5~45.1) | 9.6 (7.2~13.4) | 18.1 (15.3~21.8) | 6.4 (5.0~7.0) | |
放疗后 | 15.3 (13.2~27.9)* | 62.0 (60.0~84.5)* | 40.9 (36.8~43.4) | 9.4 (7.6~10.4) | 22.6 (15.4~26.3) | 5.8 (4.5~6.4) | |
重离子放疗同步 内分泌治疗 | 13 | ||||||
放疗前 | 17.9 (12.7~25.6) | 85.0 (75.0~93.0) | 44.8 (43.0,45.5) | 11.1 (9.3~13.2) | 20.2 (17.8~23.2) | 6.6 (5.1~7.3) | |
放疗后 | 17.2 (9.6~21.4) | 78.0 (74.0~88.0) | 45.7 (44.2,46.0) | 9.2 (8.5~11.0) | 19.6 (15.4~21.2) | 5.8 (5.5~6.7) |
治疗方案 | 例数 | ALT/(U/L) | Cr/(μmol/L) | Alb(g/L) | TB/(μmol/L) | AST/(U/L) | Cr/(μmol/L) |
---|---|---|---|---|---|---|---|
光子放疗同步 内分泌治疗 | 15 | ||||||
放疗前 | 12.6 (10.8~19.9) | 75.0 (64.0~84.0) | 42.7 (38.5~45.1) | 9.6 (7.2~13.4) | 18.1 (15.3~21.8) | 6.4 (5.0~7.0) | |
放疗后 | 15.3 (13.2~27.9)* | 62.0 (60.0~84.5)* | 40.9 (36.8~43.4) | 9.4 (7.6~10.4) | 22.6 (15.4~26.3) | 5.8 (4.5~6.4) | |
重离子放疗同步 内分泌治疗 | 13 | ||||||
放疗前 | 17.9 (12.7~25.6) | 85.0 (75.0~93.0) | 44.8 (43.0,45.5) | 11.1 (9.3~13.2) | 20.2 (17.8~23.2) | 6.6 (5.1~7.3) | |
放疗后 | 17.2 (9.6~21.4) | 78.0 (74.0~88.0) | 45.7 (44.2,46.0) | 9.2 (8.5~11.0) | 19.6 (15.4~21.2) | 5.8 (5.5~6.7) |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
DOI URL |
[2] |
ISHIKAWA H, TSUJI H, KAMADA T, et al. Carbon ion radiation therapy for prostate cancer:results of a prospective phase Ⅱ study[J]. Radiother Oncol, 2006, 81(1):57-64.
DOI URL |
[3] |
LIERMANN J, NAUMANN P, WEYKAMP F, et al. Effectiveness of carbon ion radiation in locally advanced pancreatic cancer[J]. Front Oncol, 2021, 11:708884.
DOI URL |
[4] | MURATA H, OKONOGI N, WAKATSUKI M, et al. Long-term outcomes of carbon-ion radiotherapy for malignant gynecological melanoma[J]. Cancers(Basel), 2019, 11(4):482. |
[5] |
ZHANG Y, LI P, YU Q, et al. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer[J]. Radiat Oncol, 2019, 14(1):94.
DOI PMID |
[6] |
NAKAMURA N, KUSUNOKI Y, AKIYAMA M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay[J]. Radiat Res, 1990, 123(2):224-227.
DOI URL |
[7] | Common terminology criteria for adverse eventsCTCAE v5.0[Z]. 2017. |
[8] |
MOCK U, BOGNER J, GEORG D, et al. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy[J]. Strahlenther Onkol, 2005, 181(7):448-455.
PMID |
[9] | 黄林, 何娟. PD-1/PD-L1抑制剂与前列腺癌免疫治疗的研究进展[J]. 中华男科学杂志, 2020, 26(10):944-948. |
[10] | 李晓颖, 高献书, 李洪振, 等. 放疗联合内分泌治疗期间前列腺癌患者血红蛋白降低影响因素及对预后影响[J]. 中华放射肿瘤学杂志, 2020, 29(12):1043-1047. |
[11] |
PIGNALOSA D, LEE R, HARTEL C, et al. Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions[J]. Radiother Oncol, 2013, 109(2):256-261.
DOI PMID |
[12] |
NOMIYA T, TSUJI H, KAWAMURA H, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer:a report from the Japan Carbon ion Radiation Oncology Study Group(J-CROS)[J]. Radiother Oncol, 2016, 121(2):288-293.
DOI URL |
[13] | 陆嘉德, 叶明, 郭小毛, 等. 质子重离子肿瘤放疗的临床注册试验初步报告[J]. 中华肿瘤杂志, 2018, 40(1):52-56. |
[14] | 张一贺, 张雁山, 李小军, 等. 碳离子治疗复发胸腺癌产生远隔效应临床观察1例[J]. 中国肿瘤临床, 2021, 48(20):1075-1076. |
[15] | HASEGAWA A, KOTO M, TAKAGI R, et al. Heavy ion(carbon ion) radiotherapy for skull base chordomas[J]. Jpn J Neurosurg(Tokyo), 2015, 24:528-534. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||